Novel Adeno-associated Virus Vectors Energizing Neuroscience

Share this:
Published: 15 Jun 2018

This edition of the Genetic Technology TOE provides insights across new gene therapy technologies enabling enhanced management of neurological disorders. The service encompasses the impact and opportunity of gene therapy technologies in the neuroscience industry, while providing an overview of IP and R&D trends in this space. Additionally, this TOE analyzes gene therapy methods and profiles Voyager Therapeutics, US. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Adeno-associated virus gene therapy, AAV vector, gene delivery, biomanufacturing, neuroscience, central nervous system, Tauopathies, Alzheimer’s disease, PSP, FTD, chronic pain, Friedreich’s ataxia, Parkinson’s disease, Huntington’s disease, monogenic ALS



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..